Please assess the completion status of the following clinical trial:

Trial Title: Edwards SAPIEN-3 Periprosthetic Leakage Evaluation Versus Medtronic CoreValve in Transfemoral Aortic Valve Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~In order to be eligible to participate in this study, subjects must meet all of the following criteria:~* Patient is ≥18 years of age and diagnosed with severe symptomatic aortic stenosis, judged inoperable or at high surgical risk (EuroSCORE \> 15% or other criteria that make surgery high risk by a consensus among cardiologists and cardiac surgeons in the heart team) and deemed eligible for transfemoral-TAVI.~* Aortic annulus diameter ≥ 18 and ≤ 29 mm as assessed with MSCT.~* No contraindications to study requirements such as MRI or TEE.~Exclusion criteria~* Patients unable or unwilling to give informed consent.~* Patients who are excluded from this study because of the size of their aortic annulus diameter.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edwards SAPIEN bioprosthesis (Type: ACTIVE_COMPARATOR): Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
- Medtronic CoreValve® system (Type: ACTIVE_COMPARATOR): Transcatheter aortic valve replacement with the Medtronic CoreValve system

Based on this trial design, predict the completion outcome and termination type (if applicable).